Nvidia-Backed AI Drugmaker Iambic Files for IPO, Unveiling Cancer Drug Progress and Big Pharma Deals

Iambic Therapeutics, the AI-driven drug discovery firm backed by chip giant Nvidia and Qatar Investment Authority, has officially filed for its Initial Public Offering (IPO) on the Nasdaq. This move reveals fresh details on its clinical pipeline, including the progress of its lead cancer drug candidate, IAM1363, and growing partnerships with major pharmaceutical companies, signaling a maturing landscape for artificial intelligence in medicine. The San Diego-based company's S-1 filing outlines its intent to accelerate three early-stage cancer programs using the IPO proceeds. The filing arrives amidst a bustling 2026 biotech IPO market, which has seen 21 deals raise approximately $6.5 billion so far this year, underscoring strong investor confidence in platform-stage companies like Iambic. Iambic leverages proprietary AI models such as NeuralPLexer and Enchant to dramatically speed up drug development, a process traditionally taking over a decade. Its existing 'Big Pharma partnerships' with companies like AbbVie, Takeda, and Lundbeck, which have generated increasing upfront payments, highlight the industry's keen interest in integrating AI into their research and development efforts. Looking ahead, Iambic plans to channel its IPO funds directly into advancing its oncology candidates, with the lead drug IAM1363 potentially moving into a registrational trial as early as next year. Additionally, the company expects to file Investigational New Drug (IND) applications for two more preclinical programs, IAM217 and IAM-C1, in the fourth quarter of 2026. This strategic funding will be crucial as Iambic aims to expand its clinical operations and further validate its 'molecular superintelligence' platform in the race to bring innovative medicines to patients faster.